DFTX Stock Price | Definium Therapeutics, Inc. P/E, Revenue, EPS, & Forecasts

Definium Therapeutics, Inc. • DFTX

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Definium Therapeutics, Inc.

Ticker

DFTX

Trading on

NASDAQ

ISIN

Industry

Biotechnology

Sector

Healthcare

CEO

Robert Barrow

Headquarters

One World Trade Center, New York, NY, United States, 10007

Employees

105

Website

https://definiumtx.com

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

Metrics

BasicAdvanced

Market cap

$2.19B

P/E ratio

EPS

-$2.06

Dividend Yield

0.00%

Beta

2.56

Forward P/E ratio

EBIDTA

$-166M

Ex dividend date

Price & volume

Market cap

$2.19B

Average daily volume

1.7M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

6.58

Earnings

EPS

-$2.06

EPS estimate (current quarter)

-$0.49

EPS estimate (next quarter)

-$0.44

EBITDA

$-166M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

2.56

52-week High

$23.04

52-week Low

$5.45

50-day moving average

$18.30

200-day moving average

$13.14

Short ratio

9.47

Short %

15.14%

Management effectiveness

ROE (TTM)

-64.06%

ROA (TTM)

-28.01%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

99.7M

Float

93.7M

Insiders %

1.39%

Institutions %

71.81%

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.35

-$0.34

-2.94%

Q1 • 25Missed

-$0.50

-$0.37

-35.14%

Q2 • 25Missed

-$0.78

-$0.50

-56.00%

Q3 • 25Missed

-$0.50

-$0.51

1.15%

Q4 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-67.3M

-∞%

Q3 • 25

$0M

$-50.4M

-∞%

Q4 • 25

NaN%

-25.02%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$237M

$106M

44.88%

Q3 • 25

$440M

$108M

24.49%

Q4 • 25

85.76%

1.37%

-45.43%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-29.6M

$15.4M

$0.7M

$-29.6M

Q3 • 25

$-41.9M

$35M

$247M

$-41.9M

Q4 • 25

41.68%

127.08%

32,826.17%

41.68%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Definium Therapeutics, Inc. share?

Definium Therapeutics, Inc. shares are currently traded for undefined per share.

How many shares does Definium Therapeutics, Inc. have?

Definium Therapeutics, Inc. currently has 99.7M shares.

Does Definium Therapeutics, Inc. pay dividends?

No, Definium Therapeutics, Inc. doesn't pay dividends.

What is Definium Therapeutics, Inc. 52 week high?

Definium Therapeutics, Inc. 52 week high is $23.04.

What is Definium Therapeutics, Inc. 52 week low?

Definium Therapeutics, Inc. 52 week low is $5.45.

What is the 200-day moving average of Definium Therapeutics, Inc.?

Definium Therapeutics, Inc. 200-day moving average is $13.14.

Who is Definium Therapeutics, Inc. CEO?

The CEO of Definium Therapeutics, Inc. is Robert Barrow.

How many employees Definium Therapeutics, Inc. has?

Definium Therapeutics, Inc. has 105 employees.

What is the market cap of Definium Therapeutics, Inc.?

The market cap of Definium Therapeutics, Inc. is $2.19B.

What is the P/E of Definium Therapeutics, Inc.?

The current P/E of Definium Therapeutics, Inc. is null.

What is the EPS of Definium Therapeutics, Inc.?

The EPS of Definium Therapeutics, Inc. is -$2.06.

What is the PEG Ratio of Definium Therapeutics, Inc.?

The PEG Ratio of Definium Therapeutics, Inc. is null.